



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/516,476

05/16/2005

Reinhard Ebner

689290-227

7784

7590

04/10/2007

Alan J Grant
Carella Byrne Bain Gilfillan Cecchi
Stewart & Olstein
6 Becker Farm Road
Roseland, NJ 07068

EXAMINER

DAVIS, MINH TAM B

ART UNIT

PAPER NUMBER

1642

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
--	-----------	---------------

31 DAYS

04/10/2007

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary	Application No. 10/516,476	Applicant(s) EBNER ET AL.	
	Examiner MINH-TAM DAVIS	Art Unit 1642	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 16 May 2005.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-36 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) _____ is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claim(s) 1-36 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group 1. Claims 1-7, 36, drawn to an *in vitro* screening of a modulator of the nucleic acid SEQ ID NO:1.

Groups 2-20. Claims 1-7, 36, drawn to an *in vitro* screening of a modulator of the nucleic acid SEQ ID NO:2-7, 14-20, 27-33. A method using each of the nucleic acid constitutes a single, distinct invention.

Groups 21-40. Claims 1-7, 36, drawn to an *in vitro* screening of a modulator of the polypeptide encoded by the nucleic acid SEQ ID NO:1-7, 14-20, 27-33. A method using each of the polypeptide constitutes a single, distinct invention.

Groups 41-60. Claim 8, drawn to an *in vivo* screening of a modulator of the nucleic acid SEQ ID NO:1-7, 14-20, 27-33. A method using each of the nucleic acid constitutes a single, distinct invention.

Groups 61-80. Claim 8, drawn to an *in vivo* screening of a modulator of the polypeptide encoded by the nucleic acid SEQ ID NO:1-7, 14-20, 27-33. A method using each of the polypeptide constitutes a single, distinct invention.

Art Unit: 1642

Groups 81-100. Claims 9-10, drawn to a method for detecting cancer, comprising detecting the mRNA level of expression of the nucleic acid SEQ ID NO:1-7, 14-20, 27-33. A method using each of the polypeptide constitutes a single, distinct invention.

Groups 101-120. Claims 9-10, drawn to a method for detecting cancer, comprising detecting the protein level of expression of the polypeptide encoded by the nucleic acid SEQ ID NO:1-7, 14-20, 27-33. A method using each of the polypeptide constitutes a single, distinct invention.

Groups 121-140. Claims 11-12, 27-29, drawn to a polypeptide, SEQ ID NO: 8-13, 21-26, 34-39. Each polypeptide constitutes a single, distinct invention.

Groups 141-160. Claims 13-23, drawn to an antibody to a polypeptide, SEQ ID NO: 8-13, 21-26, 34-39. An antibody to each polypeptide constitutes a single, distinct invention.

Groups 161-180. Claims 24-26, 29, drawn to a method for treating cancer, using an antibody to the polypeptide encoded by the nucleic acid SEQ ID NO:1-7, 14-20, 27-33. A method using an antibody to each of the polypeptide constitutes a single, distinct invention.

Groups 181-200. Claims 30-31, drawn to a method for treating cancer, using a polypeptide SEQ ID NO: 8-13, 21-26, 34-39. A method using each polypeptide constitutes a single, distinct invention.

Groups 201-219. Claim 32, drawn to a method for treating cancer, using an in vivo modulator of a nucleic acid SEQ ID NO: 1-7, 14-20, 27-33. A method using each of the modulators constitutes a single, distinct invention.

Art Unit: 1642

Groups 220-239. Claim 32, drawn to a method for treating cancer, using an in vivo modulator of a polypeptide encoded by a nucleic acid SEQ ID NO: 1-7, 14-20, 27-33. A method using each of the modulators constitutes a single, distinct invention.

Groups 240-259. Claims 33-35, drawn to a method for preventing cancer, using an in vivo modulator of a nucleic acid SEQ ID NO: 1-7, 14-20, 27-33. A method using each of the modulators constitutes a single, distinct invention.

Groups 260-279. Claims 33-35, drawn to a method for preventing cancer, using an in vivo modulator of a polypeptide encoded by a nucleic acid SEQ ID NO: 1-7, 14-20, 27-33. A method using each of the modulators constitutes a single, distinct invention.

The inventions are distinct, each from the other because of the following reasons:

A national stage application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept. When claims to different categories are present in the application, the claims will be considered to have unity of invention if the claims are drawn only to one of the following combinations of categories: (1) A product and a process specially adapted for the manufacture of said product; or (2) A product and a process of use of said product; or (3) A product, a process specially adapted for the manufacture of the said product, and a use of the said product; or (4) A process and an apparatus or means specifically designed for carrying out the said process; or (5) A product, a process specially adapted for the manufacture of the said product, and an apparatus or means specifically designed for carrying out the said process. If multiple products, processes of manufacture or uses are claimed, the first invention of the category first mentioned in the claims of the application will be considered as the main invention in the claims, see PCT article 17(3) (a) and 1.476 (c), 37 C.F.R. 1.475(b) and

(d). Group I will be the main invention. After that, all other products and methods will be broken out as separate groups (see 37 CFR 1.475(d).)

Group I, claims 1-7, 36 forms a single general inventive concept.

Groups 41, 81 are additional use of the nucleic acid SEQ ID NO:1.

Groups 2-40, 42-80, 82-120, 161-279 do not share the same technical feature of group I, because the methods of groups 2-40, 42-120, 161-279 do not use the nucleic acid SEQ ID NO:1 of group I.

Groups 121-160 do not share the same technical feature of group I, because the composition of groups 121-160 do not share a common structure with of the nucleic acid SEQ ID NO:1 of group I.

Accordingly, Groups 1-279 are not so linked by the same or a corresponding special technical feature as to form a single general inventive concept.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Art Unit: 1642


Any inquiry concerning this communication or earlier communications from the examiner should be directed to MINH-TAM DAVIS whose telephone number is 571-272-0830. The examiner can normally be reached on 9:00 AM-5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, SHANON FOLEY can be reached on 571-272-0898. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

MINH TAM DAVIS

March 27, 2007


SHANON FOLEY
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600